PB
Therapeutic Areas
Parion Sciences Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Idrevloride (P-1037) | Primary Ciliary Dyskinesia (PCD) | Phase 2 |
| ENaC Blocker Platform | Cystic Fibrosis and other pulmonary diseases | Research to Clinical |
| tPAD | Not specified (platform technology) | Research |
| Mucolytic Agents | Not specified | Research |